Ofatumumab (Arzerra) in clinical studies for Multiple Sclerosis (MS)
Ofatumumab is an antibody against a protein called CD20, which is found on the surface of certain types of immune cells…
Rebif Cost-effective and Can Reduce Brain Lesions in RRMS Patients, Data Show
Merck KGaA presented new evidence supporting the safety and clinical efficacy of Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis (RRMS) at the 5th Congress of the European…
Stuart Schlossman
Disease Modifying Therapies in the over 60s
Sophie McConnell 28 May 2019 Dr Jonathan White explains the results of two separate studies which looked at treatment of…
Stuart Schlossman
Video: MS Medications – Which Multiple Sclerosis Drugs Need a Washout?
In this video @AaronBosterMD teach you about washout periods for each of the MS medications. :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: To receive ‘The MS BEACON’ e-Newsletter, Click…
Stuart Schlossman
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Interim EVOLVE-MS-1 Data Support Efficacy, Tolerability of Diroximel Fumarate in Relapsing Multiple Sclerosis Diroximel fumarate may be an effective treatment…
Stuart Schlossman
Accessing your medicines (MS and non-MS) can be confusing. BUT It doesn’t have to be.
PhRMA member companies are committed to helping patients make more informed health care decisions by providing more transparency about medicine…
Stuart Schlossman
PhRMA Launches New Website to Provide Patients with Medicine Cost Information
Washington, D.C. (May 8, 2019) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Steven J. Ubl issued the…
Stuart Schlossman
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A1, Bass AD2, Nadj C3, Agius MA4, Steingo B5, Selmaj KW6, Thoits T7, Guerreiro A8, Van Wijmeersch B9, Ziemssen T10, Meuth SG11, LaGanke CC12, Thangavelu K13, Rodriguez CE13,14, Baker DP13, Margolin DH13,15, Jannsens A16. Author…
Stuart Schlossman
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease.
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease. This…
Stuart Schlossman
Mapi Pharma to Host Key Opinion Leader Meeting on LONG ACTING Glatiramer Acetate (GA Depot) for Primary Progressive Multiple Sclerosis and New Treatments for MS
NESS ZIONA, Israel, Feb. 21, 2019 (GLOBE NEWSWIRE) — Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company,…
Stuart Schlossman
